2023 (39 POSTS)

Meek ME, Wikoff D. 2023. The need for good practice in the application of mechanistic constructs in hazard and risk assessment. Toxicol Sci kfad039.

View Abstract

Dalvi T, Nørgaard M, Fryzek JP, Movva N, Pedersen L, Hansen HP, et al. 2023. Biomarker expression and survival in patients with non-small cell lung cancer receiving adjuvant chemotherapy in Denmark. PLoS ONE 18(4):e0284037; doi: 10.1371/journal.pone.0284037.

View Abstract

Thompson CM, Heintz MM, Wolf JC, Cheru R, Haws LC, Cullen JM. 2023. Assessment of mouse liver histopathology following exposure to HFPO-DA with emphasis on understanding mechanisms of hepatocellular death. Toxicol Pathol 51(1–2):4–14; doi: 10.1177/01926233231159078.

View Abstract

Heintz MM, Haws LC, Klaunig JE, Cullen JM, Thompson CM. 2023. Assessment of the mode of action underlying development of liver lesions in mice following oral exposure to HFPO-DA and relevance to humans. Toxicol Sci 192(1):15–29; doi: 10.1093/toxic/kfad004.

View Abstract

Thompson CM, Proctor DM, Harris MA. 2023. Letter to “Chepelev et al. Establishing a quantitative framework for regulatory interpretation of genetic toxicity dose–response data: Margin of exposure case study of 48 compounds with both in vivo mutagenicity and carcinogenicity dose–response data.” Environ Mol Mutagen 64(4):259–260; doi: 10.1002/em.22537.

Sterner TR, Covington TR, Mattie DR. 2023. Complex mixtures: Array PBPK modeling of jet fuel components. Toxics 11:187. https://doi.org/10.3390/toxics11020187.

View Abstract

East A, Dawson DE, Brady S, Vallero DA, Tornero-Velez R. 2023. A scoping assessment of implemented toxicokinetic models of per- and polyfluoro-alkyl substances, with a focus on one-compartment models. Toxics 11(2):163; doi: 10.3390/toxics11020163.

View Abstract

Grover A, Sankaranarayanan S, Mathur V, Suri P, Qiu H, Andrews-Zwilling Y, Mease K, Taylor LK, Cahir-McFarland E, Keswani S, Yednock T. 2023. Pharmacokinetic and target engagement measures of ANX007, an anti-C1q antibody fragment, following intravitreal administration in nonhuman primates. Invest Opthalmol Visual Sci 64(2)3; 10.1167/iovs.64.2.3.

View Abstract

Borghoff SJ, Cohen SS, Jiang X, Lea IA, Klaren WD, Chappell GA, Britt JK, Rivera BN, Choksi NY, Wikoff DS. 2023. Updated systematic assessment of human, animal and mechanistic evidence demonstrates lack of human carcinogenicity with consumption of aspartame. Food Chem Toxicol 172:113549, online ahead of print.

View Abstract

Godínez-Oviedo A, Sampedro F, Bowman JP, Garcés-Vega FJ, Hernández-Iturriaga M. 2023. Genotypic and phenotypic quantitative microbial risk assessment model of human salmonellosis related to the consumption of chicken meat in the central region of Mexico. Food Res Int 162(A):111901, https://doi.org/10.1016/j.foodres.2022.111901.

View Abstract

Bullano M, Cool C, Schultz BG, Durgapal S, Sacks N, Liu Y, Kee R, Batt K. 2023. Evaluating the financial impact of utilizing recombinant porcine factor VIII or recombinant DVIIa for patients with acquired hemophilia A. Expert Rev Phamacoecon Outcome Res 23(2):225-230; doi: 10.1080/14737167.2023.2160705.

View Abstract

2022 (59 POSTS)

Doepker C, Movva N, Cohen SS, Wikoff DS. 2022. Benefit-risk of coffee consumption and all-cause mortality: A systematic review and disability adjusted life year analysis. Food Chem Toxicol 170(Dec):113472; doi: 10.1016/j.fct.2022.113472.

View Abstract

Boles C, Zisook R, Buerger AN, Hamaji C, Mathis C, Lauer D, et al. 2022. Semi-quantitative microbial risk assessment: a narrative review and proposed framework for health and safety practitioners. Journal of Public Health and Emergency 6:34.

View Abstract

Broome CM, Hooda N, Su J, Jiang X, Nicholson G, Frankenfeld CL, Iglesias-Rodriguez M, Fryzek J, Patel Parija. 2022. Medically-attended anxiety and depression is increased among newly diagnosed patients with cold agglutinin disease: Analysis of an integrated claim-clinical cohort in the United States. PLoS One 17(12):e0276617; doi: 10.1371/journal.pone.0276617.

View Abstract

Cardosi L, Rau R, Emdem MR, Kemp R, Minshall M, Pontenani F, Provision S, Sacks N. 2022. Healthcare resource utilization in non-cystic fibrosis bronchiectasis (NCFB) patients with commercial insurance coverage in the US. Value in Health 25(12). Supplement. S1:S546, DOI: 10.1016/j.jval.2022.09.437, online article.

View Abstract

Gillezeau C, Movva N, van Gerwen M, Rabon-Stith K, Shire N, Brohawn PZ, Taioli E, Fryzek J. 2022. Interferon gamma expression and mortality in unselected cohorts of urothelial bladder cancer patients. PLoS One 17(8):e0271339; doi: 10.1371/journal.pone.0271339. PMID: 36040901; PMCID: PMC9426882.

View Abstract

Cohen SS, Bylsma LC, Movva N, Alexander DD. 2022. Theoretical attributable risk analysis and Disability Adjusted Life Years (DALYs) based on increased dairy consumption. BMC Public Health 22(1):1625, doi: 10.1186/s12889-022-14042-7.

View Abstract

Heintz MM, Chappell GA, Thompson CM, Haws LC. 2022. Evaluation of transcriptomic responses in livers of mice exposed to the short-chain PFAS compound HFPO-DA. Front Toxicol 4:937168; https://doi.org/10.3389/ftox.2022.937168.

View Abstract

Goyak KO, Sarang SS, Franzen A, Borghoff SJ, Ryman-Rasumssen JP. 2022. Adverse outcome pathway (AOP): α2u-globulin nephropathy and kidney tumors in male rats. Crit Rev Toxicol 52(5):345-357; doi: 10.1080/10408444.2022.2082269. PMID: 35862579.

View Abstract

Lynch HN, Lauer DJ, Thompson WJ, Leleck O, Freid RD, Collins J, Chen K, et al. 2022. Systematic review of the scientific evidence of the pulmonary carcinogenicity of talc. Front Public Health 10:989111; doi: 10.3389/fpubh.2022.989111.

View Abstract